Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Writing guidelines without a net: ECD

Oussama Abla, Robert Arceci

Blood (2014) 124 (4): 472–474.

https://doi.org/10.1182/blood-2014-06-578997

Published: 2014

Journal Articles

Prevalence and Prognostic Significance of c-KIT Mutations in Pediatric CBF AML Patients Enrolled on Serial CCG/COG Protocols.

Jessica Pollard, Todd Alonzo, Robert Gerbing, Rong Zeng, Betsy Hirsch, Susana Raimondi, Nyla Heerema, William Woods, Beverly Lange, Craig Hurwitz, Robert Arceci, Jerald Radich, Irwin Bernstein, Michael Heinrich, Soheil Meshinchi

Blood (2007) 110 (11): 1442.

https://doi.org/10.1182/blood.V110.11.1442.1442

Published: 2007

Journal Articles

Outcome of Down Syndrome (DS) Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Treated with a Uniform Prospective Clinical Trial - Initial Report of the COG Trial A2971.

Alan S. Gamis, MD, Todd A. Alonzo, PhD, Joanne M. Hilden, MD, Robert B. Gerbing, MA, Thomas W. Loew, MD, Lois Hathaway, CCRP, Loris McGavran, PhD, Dorothy Barnard, MD, Jeffrey W. Taub, MD, Yaddanapudi Ravindranath, MD, Franklin O. Smith, MD, Robert Arceci, MD, PhD

Blood (2006) 108 (11): 15.

https://doi.org/10.1182/blood.V108.11.15.15

Published: 2006

Journal Articles

Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Childrens Oncology Group Study.

Patrick Brown, MD, Emily McIntyre, Rachel Rau, MD, Todd A. Alonzo, PhD, Robert Gerbing, MA, Soheil Meshinchi, MD PhD, Norman Lacayo, MD, Myron Chang, PhD, Robert Arceci, MD PhD, Donald Small, MD PhD

Blood (2006) 108 (11): 221.

https://doi.org/10.1182/blood.V108.11.221.221

Published: 2006

Journal Articles

TBI and Allogeneic BMT Do Not Appear To Hinder Growth in Pediatirc Patients with AML Treated on POG 9421 (Now Children’s Oncology Group).

Kimo Stine, MD, David Becton, MD, Gary Van Houten Dahl, MD, Yaddanapudi Ravindranath, MD, Susana C. Raimondi, PhD, Fred Behm, MD, Myron Chang, Robert Arceci, MD

Blood (2006) 108 (11): 3677.

https://doi.org/10.1182/blood.V108.11.3677.3677

Published: 2006

Journal Articles

Clofarabine in Children with Refractory/Relapsed Acute Leukemia: Results of 2 Phase II Open Label Studies.

Sima Jeha, Bassem Razzouk, Paul Gaynon, Michael Rytting, Richard Kadota, Susan Rheingold, Lori Luchtman-Jones, Robert Arceci, Peter Steinherz

Blood (2006) 108 (11): 4460.

https://doi.org/10.1182/blood.V108.11.4460.4460

Published: 2006

Journal Articles

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition

Patrick Brown, Soheil Meshinchi, Mark Levis, Todd A. Alonzo, Robert Gerbing, Beverly Lange, Robert Arceci, Donald Small

Blood (2004) 104 (6): 1841–1849.

https://doi.org/10.1182/blood-2004-03-1034

Published: 2004

NARROW

Writing guidelines without a net: ECD

Prevalence and Prognostic Significance of c-KIT Mutations in Pediatric CBF AML Patients Enrolled on Serial CCG/COG Protocols.

Outcome of Down Syndrome (DS) Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Treated with a Uniform Prospective Clinical Trial - Initial Report of the COG Trial A2971.

Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Childrens Oncology Group Study.

TBI and Allogeneic BMT Do Not Appear To Hinder Growth in Pediatirc Patients with AML Treated on POG 9421 (Now Children’s Oncology Group).

Clofarabine in Children with Refractory/Relapsed Acute Leukemia: Results of 2 Phase II Open Label Studies.

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition

Email alerts

ASH Publications

American Society of Hematology

Writing guidelines without a net: ECD

Prevalence and Prognostic Significance of c-KIT Mutations in Pediatric CBF AML Patients Enrolled on Serial CCG/COG Protocols.

Outcome of Down Syndrome (DS) Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Treated with a Uniform Prospective Clinical Trial - Initial Report of the COG Trial A2971.

Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Childrens Oncology Group Study.

TBI and Allogeneic BMT Do Not Appear To Hinder Growth in Pediatirc Patients with AML Treated on POG 9421 (Now Children’s Oncology Group).

Clofarabine in Children with Refractory/Relapsed Acute Leukemia: Results of 2 Phase II Open Label Studies.

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only